Seeking Alpha

Cowen says Alkermes (ALKS +2.4%) should be bought at current levels , citing the value of its...

Cowen says Alkermes (ALKS +2.4%) should be bought at current levels , citing the value of its diabetes drug Bydureon and its potential profitability for the company. The firm believes the royalty stream could be worth more than $1B, or $8 per share, which would drive significantly higher valuations.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|